About Damaira
Damaira is a Healthcare company based in India. It manufactures Carbapenem dry powder injections for treating severe and complicated bacterial infections. It operates on a B2B model. The company has 64 employees. Its Indian entity Damaira Pharmaceuticals Private Limited reported revenue of ₹82.77 Cr. Damaira offers products and services including Meropenem, Imipenem Cilastatin, Doripenem, Ertapenem, and Biapenem. Its focus areas include Pharmaceuticals, Drug Manufacturing, Injections Production and Antibiotics.
Company details
Damaira Pharmaceuticals specializes in producing Carbapenem dry powder injections, a class of antibiotics for severe bacterial infections. They operate a state-of-the-art facility in Panchkula, Haryana, India, adhering to strict regulatory standards for quality and safety. The company focuses on innovation, research, and sustainability to ensure affordable, high-quality medicines. They serve healthcare providers and aim for minimal environmental impact through controlled production processes.
- Headquarters India
- Employees 64
- SectorsHealthcare
- Email••••••••
- Website damaira.com
- Legal Name Damaira Pharmaceuticals Private Limited
- Date of Incorporation 29 Jul, 2020
- Jurisdiction Chandigarh, India
- Annual Revenue₹82.77 Cr
FY 2025 · +229% YoY
- Net Profit₹71.7 Lakh
FY 2025 · 1% margin
- EBITDA₹7.66 Cr
FY 2025 · 9% margin
- Employee Count64
Associated legal entities of Damaira
Damaira operates through Damaira Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Damaira Pharmaceuticals Private Limited CIN U24230CH2020PTC043119 | Active | 29 Jul 2020 | Chandigarh, Chandigarh | ₹82.8 Cr | 64 | 3 | View details |
Products & Services of Damaira
Damaira offers a comprehensive portfolio of products and services, including Meropenem, Imipenem Cilastatin, Doripenem, Ertapenem, and Biapenem.
Dry powder injection for treating severe bacterial infections effectively.
Combination injection to combat complicated bacterial infections.
Injection used for severe infections in critical care settings.
Dry powder for treating various bacterial infections.
Injection targeted at resistant bacterial strains.
Board of directors of Damaira Pharmaceuticals Private Limited (Damaira)
Damaira Pharmaceuticals Private Limited is the primary company behind Damaira. The board of Damaira Pharmaceuticals Private Limited currently have 3 directors; the longest-serving is Vikul Bansal, appointed in 2020. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vikul Bansal DIN 08247570 | Managing Director | 29 Jul 2020 | 6 yrs 3 mo | Damaira Pharmaceuticals Private Limited |
| Manik Bansal DIN 09803902 | Director | 08 Dec 2022 | 3 yrs 11 mo | Damaira Pharmaceuticals Private Limited |
| Ashish Sharma DIN 10392387 | Additional Director | 13 Nov 2023 | 3 yrs | Damaira Pharmaceuticals Private Limited |
Financials of Damaira
Figures of Damaira Pharmaceuticals Private Limited, the primary company behind Damaira, for FY 2025. Revenue was ₹82.77 Cr (+229% year on year). Net profit was ₹71.7 Lakh (1% margin). EBITDA was ₹7.66 Cr (9% margin). Revenue has grown at a compounded annual rate of +645% over three years.
- ₹82.77 CrRevenue · FY 2025 · +229% YoY
- ₹71.7 LakhNet profit · 1% margin
- ₹7.66 CrEBITDA · 9% margin
- ₹7.00 CrPaid-up capital
- 64Employees (provident fund records)
- +645%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Damaira Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for Damaira
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Damaira
Damaira is headquartered in India.
Damaira has 64 employees.
The primary company behind Damaira, Damaira Pharmaceuticals Private Limited, reported revenue of ₹82.77 Cr for FY 2025, up 229% year on year.
Damaira Pharmaceuticals specializes in producing Carbapenem dry powder injections, a class of antibiotics for severe bacterial infections. They operate a state-of-the-art facility in Panchkula, Haryana, India, adhering to strict regulatory standards for quality and safety. The company focuses on innovation, research, and sustainability to ensure affordable, high-quality medicines. They serve healthcare providers and aim for minimal environmental impact through controlled production processes.
Damaira offers Meropenem, Imipenem Cilastatin, Doripenem, Ertapenem, and Biapenem.
Damaira operates through Damaira Pharmaceuticals Private Limited.
The legal entities of Damaira currently have 3 directors, including Ashish Sharma, Manik Bansal, Vikul Bansal.